Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Other Non-Current Assets (2017 - 2026)

Crinetics Pharmaceuticals has reported Other Non-Current Assets over the past 9 years, most recently at $22.3 million for Q4 2025.

  • For Q4 2025, Other Non-Current Assets rose 689.22% year-over-year to $22.3 million; the TTM value through Dec 2025 reached $22.3 million, up 689.22%, while the annual FY2025 figure was $22.3 million, 689.22% up from the prior year.
  • Other Non-Current Assets for Q4 2025 was $22.3 million at Crinetics Pharmaceuticals, up from $18.4 million in the prior quarter.
  • Over five years, Other Non-Current Assets peaked at $22.3 million in Q4 2025 and troughed at $500000.0 in Q1 2021.
  • A 5-year average of $4.4 million and a median of $1.3 million in 2022 define the central range for Other Non-Current Assets.
  • Biggest five-year swings in Other Non-Current Assets: fell 0.08% in 2023 and later skyrocketed 1317.85% in 2025.
  • Year by year, Other Non-Current Assets stood at $500000.0 in 2021, then skyrocketed by 160.2% to $1.3 million in 2022, then dropped by 0.08% to $1.3 million in 2023, then soared by 117.62% to $2.8 million in 2024, then soared by 689.22% to $22.3 million in 2025.
  • Business Quant data shows Other Non-Current Assets for CRNX at $22.3 million in Q4 2025, $18.4 million in Q3 2025, and $14.9 million in Q2 2025.